TABLE 3 Cross-validated linear discriminant (LD) classification results for Salmo trutta control (C) and exercise (E) treatment groups across experimental weeks 00 (control sample before treatment initiation) to week 32 (32 weeks of treatment) derived from a LD analysis on principal component (PC) scores from a between-group PC analysis of Procrustes superimposed landmarks, corrected for the arching artefact (PC2)
| C00 | E04 | C04 | E10 | C10 | E20 | C20 | E32 | C32 | Correct (%) |
|---|
| C00 | 5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 83.33 |
|---|
| E 04 | 1 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 33.33 |
|---|
| C 04 | 1 | 1 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 50 |
|---|
| E 10 | 0 | 0 | 1 | 4 | 1 | 0 | 0 | 0 | 0 | 66.67 |
|---|
| C10 | 0 | 0 | 0 | 2 | 3 | 1 | 0 | 0 | 0 | 50 |
|---|
| E 20 | 0 | 0 | 0 | 0 | 0 | 5 | 1 | 0 | 0 | 83.33 |
|---|
| C 20 | 0 | 0 | 0 | 0 | 1 | 1 | 4 | 0 | 0 | 66.67 |
|---|
| E 32 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 50 |
|---|
| C32 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 83.33 |
|---|
| Total cross-validated | | | | | | | | | 62.96 |
|---|
| Total un-validated | | | | | | | | | 85.19 |
|---|
Numbers of correctly classified cases are shown in bold.